{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:58:34Z","timestamp":1785902314955,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.prp.2026.156359","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:12:04Z","timestamp":1767744724000},"page":"156359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Performance of the VENTANA FOLR1 Assay for folate receptor alpha: Real-world evidence from 313 Chinese participants"],"prefix":"10.1016","volume":"279","author":[{"given":"Xiaoyan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.prp.2026.156359_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca-a Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.prp.2026.156359_bib2","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"Ca-a Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.prp.2026.156359_bib3","doi-asserted-by":"crossref","first-page":"R303","DOI":"10.1530\/ERC-17-0336","article-title":"Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment","volume":"25","author":"van Zyl","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"4","key":"10.1016\/j.prp.2026.156359_bib4","first-page":"280","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA: Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.prp.2026.156359_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum\u2011based chemotherapy resistance in ovarian cancer","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.prp.2026.156359_bib6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.prp.2026.156359_bib7","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156359_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL)","volume":"163","author":"Gaillard","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2026.156359_bib9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2026.156359_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.prp.2026.156359_bib11","article-title":"FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma","volume":"36","author":"Leung","year":"2024","journal-title":"J. Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.prp.2026.156359_bib12","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.3390\/ijms26115222","article-title":"Folate receptor alpha in advanced epithelial ovarian cancer: diagnostic role and therapeutic implications of a clinically validated biomarker","volume":"26","author":"Zannoni","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.prp.2026.156359_bib13","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: mirvetuximab soravtansine-Gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156359_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"13","key":"10.1016\/j.prp.2026.156359_bib15","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.prp.2026.156359_bib16","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.5858\/arpa.2023-0149-OA","article-title":"Development of an FR\u03b1 companion diagnostic immunohistoche mical assay for mirvetuximab soravtansine","volume":"148","author":"James","year":"2024","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"7","key":"10.1016\/j.prp.2026.156359_bib17","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-\u03b1 (FR\u03b1)\u2013targeting antibody\u2013drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.prp.2026.156359_bib18","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","article-title":"Mirvetuximab soravtansine (IMGN853), a folate receptor alpha\u2013targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models","volume":"18","author":"Ponte","year":"2016","journal-title":"Neoplasia"},{"issue":"8","key":"10.1016\/j.prp.2026.156359_bib19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ijgc-2024-005401","article-title":"Mirvetuximab soravtansine in folate receptor alpha (FR\u03b1)\u2013high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial","volume":"34","author":"Coleman","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"23","key":"10.1016\/j.prp.2026.156359_bib20","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156359_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ygyno.2024.11.010","article-title":"Analysis of real world FR\u03b1 testing in ovarian, fallopian tube, and primary peritoneal cancers","volume":"192","author":"Previs","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156359_bib22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2013.03.024","article-title":"Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy","volume":"130","author":"Despierre","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.prp.2026.156359_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ygyno.2024.06.008","article-title":"Folate receptor alpha expression in low-grade serous ovarian cancer: exploring new therapeutic possibilities","volume":"188","author":"Manning-Geist","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"16","key":"10.1016\/j.prp.2026.156359_bib24","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.3390\/ijms26167687","article-title":"Interobserver agreement in immunohistochemical evaluation of folate receptor alpha (FR\u03b1) in ovarian cancer: a multicentre study","volume":"26","author":"Zannoni","year":"2025","journal-title":"Int. J. Mol."},{"key":"10.1016\/j.prp.2026.156359_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2025.03.023","article-title":"Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate","volume":"195","author":"Johannet","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156359_bib26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s10120-024-01578-3","article-title":"Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression","volume":"28","author":"Mart\u00ednez-Ciarpaglini","year":"2025","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156359_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13058-025-02001-0","article-title":"Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China","volume":"27","author":"Lv","year":"2025","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156359_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13402-011-0052-6","article-title":"The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer","volume":"35","author":"Crane","year":"2012","journal-title":"Cell. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156359_bib29","article-title":"Dedifferentiated and undifferentiated ovarian carcinoma: an aggressive and molecularly distinct ovarian tumor characterized by frequent SWI\/SNF complex inactivation","volume":"37","author":"Cloutier","year":"2024","journal-title":"Mod. Pathol."}],"updated-by":[{"DOI":"10.1016\/j.prp.2026.156422","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000}},{"DOI":"10.1016\/j.prp.2026.156422","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:57:01Z","timestamp":1770220621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":29,"alternative-id":["S0344033826000105"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156359","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance of the VENTANA FOLR1 Assay for folate receptor alpha: Real-world evidence from 313 Chinese participants","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156359"}}